Is NCT06758401 recruiting in Grand Junction, CO?

Yes, NCT06758401 is currently recruiting participants at its Grand Junction, CO location. This non-small cell lung cancer clinical trial is actively enrolling qualified participants.

How do I join the non-small cell lung cancer clinical trial in Grand Junction?

To join this clinical trial in Grand Junction, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Grand Junction clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Non-Small Cell Lung Cancer Clinical Trial in Grand Junction, CO

About This Non-Small Cell Lung Cancer Study in Grand Junction

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in

Sponsor: Pfizer

Who Can Participate

Inclusion Criteria

Participants must meet the following criteria:

Have pathologically confirmed Stage IIIB or IIIC NSCLC and not be a candidate for surgical resection or definitive chemoradiation, or Stage IV NSCLC per the AJCC Staging Manual (Version 8.0) and the UICC Staging System (Eighth edition).

Participants with non-squamous histology must have documented negative test results for EGFR, ALK, and ROS1 AGAs and no known AGAs in NTRK, BRAF, RET, MET, or other AGAs with approved front-line therapies per local standard of care.

Large cell neuroendocrine carcinoma is excluded.

Candidate for treatment with pembrolizumab monotherapy per local guidelines.

Tumor has PD-L1 expression in ≥50% of tumor cells (TPS ≥50%) as determined by local testing

Measurable disease based on RECIST v1.1 per investigator.

Resolution of acute effects of any prior therapy to either baseline severity or NCI CTCAE Grade 1 or less (except for AEs not constituting a safety risk in the investigator's judgment), unless otherwise excluded.

Exclusion Criteria

Life expectancy of \<3 months in the opinion of the investigator.

Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.

Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.

Known or suspected hypersensitivity, intolerance, or contraindication to any excipient contained in the drug formulation of sigvotatug vedotin or pembrolizumab.

Participants with any of the following respiratory conditions:

Evidence of noninfectious or drug-induced ILD or pneumonitis

Known DLCO (adjusted for hemoglobin) \<50% predicted.

Grade ≥3 pulmonary disease unrelated to underlying malignancy

Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be eligible. Clinically inactive brain metastases of longest diameter \<0.5 cm are permitted.

Major surgery (defined as a surgery requiring inpatient hospitalization of at least 48 hours) within 21 days or minor surgery within 7 days prior to first dose of study intervention.

Receipt of a live vaccine within 30 days prior to first dose of study intervention.

Pre-existing peripheral neuropathy Grade ≥2 per NCI CTCAE v5.0.

Uncontrolled diabetes mellitus, defined as HbA1c ≥8.0% or HbA1c between 7.0% and 8.0% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.

Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, required a high-dose steroid taper (≥0.5 mg/kg prednisone or equivalent per day) for \>2 weeks, or required treatment with systemic immunosuppressive therapy.

History of autoimmune disease that has required systemic treatment in the past 2 years

Participants with prior solid organ or bone marrow transplantation.

Currently receiving a high-dose steroid (\>10 mg prednisone or equivalent per day) or other immune suppressant or has a condition requiring a chronic high-dose steroid or immune suppressant.

Prior and concomitant therapy:

Any prior treatment with MMAE-derived drugs or IB6 targeting agents.

Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC.

(Neo)adjuvant anti-PD-(L)1 is allowed if recurrence or progression occurred ≥9 months after the last dose.

Other (neo)adjuvant or definitive therapy is allowed if recurrence or progression occurred ≥6 months after the last dose.

Prior radiotherapy to the lung within 6 months of first dose of study intervention, referencing the last date radiotherapy was received.

Chemotherapy, biologics, and/or other antitumor treatment with immunotherapy not specifically prohibited that is completed less than 4 weeks prior to first dose of study intervention, or 2 weeks for palliative radiotherapy.

Any prior therapy with an immune-oncology agent directed to a stimulatory or co-inhibitory T-cell receptor

History of or current ongoing infection, including participants positive for active HIV, HBV, or HCV.

Severe uncontrolled cardiac or cerebrovascular condition within the previous 6 months

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Grand Junction?

Yes, this clinical trial (NCT06758401) has an active research site in Grand Junction, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Small Cell Lung Cancer Treatment Options in Grand Junction, CO

If you're searching for non-small cell lung cancer treatment options in Grand Junction, CO, this clinical trial (NCT06758401) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Grand Junction research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced non-small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

Non-Small Cell Lung Cancer Clinical Trial in Grand Junction, CO

Expert Care in Grand Junction

IRB Approved

No-Cost Care

Apply for This Grand Junction Location

Why Participate?

Simple Process